This post is presented by our media partner Psychedelic News Wire
View the original article here.
The European Union (EU) is funding research into psychedelic-based therapies for patients with incurable diseases. Researchers will use EU funding to determine if psychedelic drugs such as psilocybin can help alleviate psychologic distress in palliative-care patients.
While palliative and end-of-life care are designed to relieve physical symptoms and make patients as comfortable as possible, there aren’t a lot of protocols to alleviate the psychological distress that often accompanies incurable illnesses. Psychedelics have exhibited significant potential as mental-health treatments in several initial studies and have shown that they can treat significant mental distress in conditions such as depression and post-traumatic stress disorder (PTSD) with few if any side effects.
EU scientists are already working on a clinical trial studying the impacts of psilocybin, the main psychoactive agent in magic mushrooms, against atypical Parkinson’s disease, multiple sclerosis, chronic obstructive pulmonary disease and amyotrophic lateral sclerosis. The EU-funded research will feature a much wider cohort of patients than previous studies to determine if psychedelics can relieve hard-to-treat depression in people with terminal conditions. This will be the first time the European Union provides full funding (more than $7 million) for a psychedelic study. The European Union will award the funding through its Horizon Europe Program.
The study will involve treating 100 patients in four sites in Portugal, the Netherlands, Denmark and the Czech Republic under the coordination of the Netherlands’ University Medical Center Groningen (UMOG). Study participants will take part in several therapy sessions and receive two doses of psilocybin starting with a lower dose followed by a higher one; some participants will receive a placebo. Unlike the majority of prior psychedelic studies, the EU-funded trial will use two doses of psilocybin instead of a single dose.
In this case, the initial smaller dose is to help patients become accustomed to the psychedelic experience before they receive the larger doses.
UMCG psychiatrist and lead investigator Robert Schoevers says the number of psychedelic trips required for the treatment to be effective is one of the major questions in the nascent psychedelic research field. He said that the researchers would explore whether a single dose followed by psychotherapy is sufficient for long-term relief.
Past studies have found that only one dose can offer respite against numerous symptoms of poor mental health, especially when the treatment is accompanied by psychotherapy. On the other hand, conventional mental-health treatments such as antidepressants usually require daily use over several weeks or even months to be fully effective, and they often cause moderate to severe side effects.
The research team will partner with health-technology assessment bodies and regulators to draw up the study protocol before beginning the trial in January 2025 and issuing its findings sometime in 2027.
The findings of this study will add onto the body of scientific data that psychedelic companies such as Compass Pathways PLC (NASDAQ: CMPS) have uncovered in their different R&D activities.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
This post was originally published by our media partner here.
